1Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol, 1994,21:2286-2291.
2Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis. The Bath ASMetrology Index. J Rheumatol, 1994,21 : 1694-1698.
3Corman JD, Sack KE, Davis JC. Treatment of anklosing spondylitis by inhbition of tumonecrosis factor alpha. New engl Enl J , Med, 2002, 346: 1349-1356.
4Inman RD, Clegg DO, Davis JC, et al. Etanercept in adultpatientswith early onset ankylosing spondylitis. J Rheumatol, 2006,33 : 1634-1636.
5Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in ptientswith ankylosing spondylitis. J Rheumatol, 2005,32: 1911-1917.
